Edition:
United Kingdom

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

1.94USD
4:55pm GMT
Change (% chg)

$0.08 (+4.30%)
Prev Close
$1.86
Open
$1.85
Day's High
$1.94
Day's Low
$1.85
Volume
118,925
Avg. Vol
408,139
52-wk High
$4.09
52-wk Low
$1.59

Latest Key Developments (Source: Significant Developments)

Antares Pharma Q3 loss per share $0.03
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Antares Pharma Inc :Antares Pharma reports third quarter 2017 operating and financial results.Q3 loss per share $0.03.Q3 revenue $15.1 million versus I/B/E/S view $14 million.Q3 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.Antares Pharma - ‍at September 30, 2017, cash, cash equivalents and short-term investments were $37.4 million compared to $27.7 million at December 31, 2016​.  Full Article

Antares Pharma receives complete response letter from FDA for Xyosted
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Antares Pharma Inc :Antares pharma receives complete response letter from the fda for Xyosted.‍CRL indicates that FDA cannot approve NDA in its present form​.‍FDA is concerned that Xyosted could cause a clinically meaningful increase in blood pressure​.‍CRL identified two deficiencies related to clinical data for Xyosted injection​.Complete response ‍letter also raised a concern regarding occurrence of depression and suicidality​.  Full Article

Antares Pharma ‍says received FDA letter regarding deficiencies of its drug Xyosted
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Antares Pharma Inc :Antares Pharma provides Xyosted™ regulatory update.Antares Pharma Inc - ‍anticipate receiving further clarification from FDA on or before prescription drug user fee act (PDUFA) date of October 20, 2017​.Antares Pharma Inc - ‍intends to work with FDA to understand nature of deficiencies once identified.Antares Pharma Inc - ‍received a letter from FDA regarding Xyosted .Antares Pharma Inc - ‍ letter from U.S. FDA does not specify deficiencies identified with respect to review of Xyosted NDA​.Antares Pharma Inc - got letter on Oct 11 stating FDA identified deficiencies precluding continuation of discussion of labeling, postmarketing needs at this time​.  Full Article

Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Antares Pharma Inc ::Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals.Antares Pharma Inc - deal for ‍up to $14.5 million​.Antares - to sell worldwide rights, including certain fixed assets, for Zomajet needle-free auto injector device to Ferring Pharmaceuticals​.Antares - deal with Ferring generates non-dilutive cash which co intends to use to invest to support launch of Xyosted​.  Full Article

Antares Pharma cfo to step down
Thursday, 11 Aug 2016 

Antares Pharma Inc : On august 5, 2016, co received written notice of resignation from james fickenscher, co's senior vice president and cfo . Company has initiated a search for a new chief financial officer - sec filing . Keith muckenhirn to assume roles of interim cfo, principal accounting officer while co completes search process for permanent cfo .Fickenscher's resignation will become effective september 4, 2016.  Full Article

Antares Pharma Q2 loss per share $0.04
Tuesday, 9 Aug 2016 

Antares Pharma Inc : Antares pharma reports second quarter 2016 operating and financial results . Q2 revenue $24.5 million . Q2 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S .Q2 revenue view $11 million -- Thomson Reuters I/B/E/S.  Full Article

Antares Pharma posts Q1 loss per share of $0.05
Monday, 9 May 2016 

Antares Pharma Inc : Antares Pharma reports first quarter 2016 operating and financial results . Q1 revenue $12.3 million versus I/B/E/S view $11.1 million . Q1 loss per share $0.05 .Q1 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.  Full Article

Antares Pharma Inc announces CEO transition
Tuesday, 26 Jan 2016 

Antares Pharma Inc:Board of Directors has appointed Robert Apple to the position of President and Chief Executive Officer.Apple succeeds Eamonn P. Hobbs.Hobbs also resigned as a member of the Board of Directors.  Full Article

BRIEF-Antares Pharma Q3 loss per share $0.03

* Antares Pharma reports third quarter 2017 operating and financial results

No consensus analysis data available.